{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:53:48Z","timestamp":1753890828647,"version":"3.41.2"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"DOI":"10.3389\/fcvm.2020.574391","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T10:40:15Z","timestamp":1604054415000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Amiodarone Induced Thyrotoxicosis and Treatment Complications in a Man With Cyanotic Congenital Heart Disease: A Case Report"],"prefix":"10.3389","volume":"7","author":[{"given":"Marvin Wei Jie","family":"Chua","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao Feng","family":"Mok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1210\/jc.2010-0180","article-title":"Approach to the patient with amiodarone-induced thyrotoxicosis","volume":"95","author":"Bogazzi","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"B2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/01.md.0000123095.65294.34","article-title":"Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland","volume":"83","author":"Kurnik","year":"2004","journal-title":"Medicine."},{"key":"B3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/2042018811398516","article-title":"Management of amiodarone-related thyroid problems","volume":"2","author":"Narayana","year":"2011","journal-title":"Ther Adv Endocrinol Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.jacc.2007.02.054","article-title":"Amiodarone-induced thyrotoxicosis: clinical course and predictors of outcome","volume":"49","author":"Conen","year":"2007","journal-title":"J Am Coll Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1046\/j.1445-5994.2003.00463.x","article-title":"Heterogeneity of amiodarone-induced thyrotoxicosis: evaluation of colour-flow doppler sonography in predicting therapeutic response","volume":"33","author":"Wong","year":"2003","journal-title":"Intern Med J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1089\/thy.1997.7.541","article-title":"Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis","volume":"7","author":"Bogazzi","year":"1997","journal-title":"Thyroid."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American thyroid association guidelines for diagnosis management of hyperthyroidism other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid."},{"key":"B8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40345-016-0068-y","article-title":"Lithium side effects and toxicity: prevalence and management strategies","volume":"4","author":"Gitlin","year":"2016","journal-title":"Int J Bipolar Disord"},{"key":"B9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1210\/edrv.22.2.0427","article-title":"The effects of amiodarone on the thyroid","volume":"22","author":"Martino","year":"2001","journal-title":"Endocr Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000486957","article-title":"2018 European Thyroid Association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction","volume":"7","author":"Bartalena","year":"2018","journal-title":"Eur Thyroid J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1210\/jcem.81.8.8768854","article-title":"Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study","volume":"81","author":"Bartalena","year":"1996","journal-title":"J Clin Endocrinol Metab."},{"key":"B12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0828-282X(09)70512-4","article-title":"Amiodarone-induced thyrotoxicosis: a review","volume":"25","author":"Tsang","year":"2009","journal-title":"Can J Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1210\/jc.2006-2059","article-title":"Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations","volume":"92","author":"Bogazzi","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"key":"B14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1365-2265.2007.02920.x","article-title":"Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy","volume":"67","author":"Bogazzi","year":"2007","journal-title":"Clin Endocrinol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1056\/NEJMra021194","article-title":"Thyroiditis","volume":"348","author":"Pearce","year":"2003","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1530\/EJE-14-0267","article-title":"The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type","volume":"171","author":"Tomisti","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1046\/j.0300-0664.2001.01457.x","article-title":"Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography","volume":"56","author":"Eaton","year":"2002","journal-title":"Clin Endocrinol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1210\/jcem.86.1.7119","article-title":"Amiodarone-induced thyrotoxicosis","volume":"86","author":"Daniels","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2265.2008.03350.x","article-title":"Benzofuran derivatives and the thyroid","volume":"70","author":"Han","year":"2009","journal-title":"Clin Endocrinol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1210\/js.2018-00259","article-title":"Thyroidectomy for amiodarone-induced thyrotoxicosis: mayo clinic experience","volume":"2","author":"Kotwal","year":"2018","journal-title":"J Endocr Soc."},{"key":"B21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1055\/s-0035-1565094","article-title":"Total thyroidectomy for amiodarone-induced thyrotoxicosis in the hyperthyroid state","volume":"124","author":"Kaderli","year":"2016","journal-title":"Exp Clin Endocrinol Diabetes."},{"key":"B22","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S0002-9343(97)00047-8","article-title":"Lithium treatment in amiodarone-induced thyrotoxicosis","volume":"102","author":"Dickstein","year":"1997","journal-title":"Am J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3803\/EnM.2016.31.3.476","article-title":"cholestyramine use for rapid reversion to euthyroid states in patients with thyrotoxicosis","volume":"31","author":"Ha","year":"2016","journal-title":"Endocrinol Metab."},{"key":"B24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1046\/j.1440-1622.2000.01780.x","article-title":"Refractory amiodarone-associated thyrotoxicosis: an indication for thyroidectomy","volume":"70","author":"Claxton","year":"2000","journal-title":"ANZ J Surg"},{"key":"B25","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1089\/105072501300176471","article-title":"The various effects of amiodarone on thyroid function","volume":"11","author":"Bogazzi","year":"2001","journal-title":"Thyroid."},{"key":"B26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2165\/00002018-200629030-00006","article-title":"Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis","volume":"29","author":"Uzan","year":"2006","journal-title":"Drug Saf."},{"key":"B27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1210\/jc.2011-2390","article-title":"Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial","volume":"97","author":"Eskes","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1210\/jc.2011-1678","article-title":"Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study","volume":"96","author":"Bogazzi","year":"2011","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2020.574391\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T10:40:16Z","timestamp":1604054416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2020.574391\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":28,"alternative-id":["10.3389\/fcvm.2020.574391"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2020.574391","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2020,10,30]]},"article-number":"574391"}}